Dong Zhiyong, Xu Jing, Wang Zhen, Petrov Maxim S
Department of Surgery, The First Affiliated Hospital of Jinan University, No.613, HuangPu Avenu West, Guangzhou, Guangdong, China, 510630.
Cochrane Database Syst Rev. 2016 May 6;2016(5):CD008914. doi: 10.1002/14651858.CD008914.pub3.
Several studies have demonstrated that the use of pancreatic duct stents following pancreaticoduodenectomy is associated with a lower risk of pancreatic fistula. However, to date there is a lack of accord in the literature on whether the use of stents is beneficial and, if so, whether internal or external stenting, with or without replacement, is preferable. This is an update of a systematic review.
To determine the efficacy of pancreatic stents in preventing pancreatic fistula after pancreaticoduodenectomy.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Web of Science, and four major Chinese biomedical databases up to November 2015. We also searched several major trials registers.
Randomized controlled trials (RCTs) comparing the use of stents (either internal or external) versus no stents, and comparing internal stents versus external stents, replacement versus no replacement following pancreaticoduodenectomy.
Two review authors independently extracted the data. The outcomes studied were incidence of pancreatic fistula, need for reoperation, length of hospital stay, overall complications, and in-hospital mortality. We showed the results as risk ratio (RR) or mean difference (MD), with 95% confidence interval (CI). We assessed the quality of evidence using GRADE (http://www.gradeworkinggroup.org/).
We included eight studies (1018 participants). The average age of the participants ranged from 56 to 68 years. Most of the studies were conducted in single centers in Japan (four studies), China (two studies), France (one study), and the USA (one study). The risk of bias was low or unclear for most domains across the studies. Stents versus no stentsThe effect of stents on reducing pancreatic fistula in people undergoing pancreaticoduodenectomy was uncertain due to the low quality of the evidence (RR 0.67, 95% CI 0.39 to 1.14; 605 participants; 4 studies). The risk of in-hospital mortality was 3% in people who did receive stents compared with 2% (95% CI 1% to 6%) in people who had stents (RR 0.73, 0.28 to 1.94; 605 participants; 4 studies; moderate-quality evidence). The effect of stents on reoperation was uncertain due to wide confidence intervals (RR 0.67, 0.36 to 1.22; 512 participants; 3 studies; moderate-quality evidence). We found moderate-quality evidence that using stents reduces total hospital stay by just under four days (mean difference (MD) -3.68, 95% CI -6.52 to -0.84; 605 participants; 4 studies). The risk of delayed gastric emptying, wound infection, and intra-abdominal abscess was uncertain (gastric emptying: RR 0.75, 95% CI 0.24 to 2.35; moderate-quality evidence) (wound infection: RR 0.73, 95% CI 0.40 to 1.32; moderate-quality evidence) (abscess: RR 1.38, 0.49 to 3.85; low-quality evidence). Subgroup analysis by type of stent provided limited evidence that external stents lead to lower risk of fistula compared with internal stents. External versus internal stentsThe effect of external stents on the risk of pancreatic fistula, reoperation, delayed gastric emptying, and intra-abdominal abscess compared with internal stents was uncertain due to low-quality evidence (fistula: RR 1.44, 0.94 to 2.21; 362 participants; 3 studies) (reoperation: RR 2.02, 95% CI 0.38 to 10.79; 319 participants; 3 studies) (gastric emptying: RR 1.65, 0.66 to 4.09; 362 participants; 3 studies) (abscess: RR 1.91, 95% CI 0.80 to 4.58; 362 participants; 3 studies). The rate of in-hospital mortality was lower in studies comparing internal and external stents than in those comparing stents with no stents. One death occurred in the external-stent group (RR 0.33, 0.01 to 7.99; low-quality evidence). There were no cases of pancreatitis in participants who had internal stents compared with three in those who had external stents (RR 0.15, 0.01 to 2.73; low-quality evidence). The difference between internal and external stents on total hospital stay was uncertain due to the wide confidence intervals around the average effect of 1.7 days fewer with internal stents (9.18 days fewer to 5.84 days longer; 262 participants; 2 studies; low-quality evidence). The analysis of wound infection could not exclude a protective effect with either approach (RR 1.41, 0.44 to 4.48; 319 participants; 2 studies; moderate-quality evidence). Operative replacement of pancreatic juice versus not replacing pancreatic juice There was insufficient evidence available from a small trial to ascertain the effect of replacing pancreatic juice.
AUTHORS' CONCLUSIONS: This systematic review has identified limited evidence on the effects of stents. We have not been able to identify convincing direct evidence of superiority of external over internal stents. We found a limited number of RCTs with small sample sizes. Further RCTs on the use of stents after pancreaticoduodenectomy are warranted.
多项研究表明,胰十二指肠切除术后使用胰管支架可降低胰瘘风险。然而,迄今为止,关于支架的使用是否有益,以及如果有益,是使用内支架还是外支架、是否更换支架更优,文献中尚无定论。这是一项系统评价的更新。
确定胰十二指肠切除术后胰管支架预防胰瘘的疗效。
我们检索了截至2015年11月的Cochrane对照试验中心注册库(CENTRAL)、MEDLINE、EMBASE、科学引文索引以及四个主要的中国生物医学数据库。我们还检索了几个主要的试验注册库。
比较使用支架(内支架或外支架)与不使用支架,以及比较胰十二指肠切除术后内支架与外支架、更换支架与不更换支架的随机对照试验(RCT)。
两位综述作者独立提取数据。研究的结局包括胰瘘发生率、再次手术需求、住院时间、总体并发症和住院死亡率。我们将结果表示为风险比(RR)或均值差(MD),并给出95%置信区间(CI)。我们使用GRADE(http://www.gradeworkinggroup.org/)评估证据质量。
我们纳入了八项研究(1018名参与者)。参与者的平均年龄在56至68岁之间。大多数研究在日本(四项研究)、中国(两项研究)、法国(一项研究)和美国(一项研究)的单中心进行。各项研究中大多数领域的偏倚风险较低或不明确。
支架与无支架
由于证据质量低,支架对降低胰十二指肠切除术后患者胰瘘的效果不确定(RR 0.67,95%CI 0.39至1.14;605名参与者;4项研究)。接受支架治疗的患者住院死亡率为3%,而使用支架的患者为2%(95%CI 1%至6%)(RR 0.73,0.28至1.94;605名参与者;4项研究;中等质量证据)。由于置信区间较宽,支架对再次手术的影响不确定(RR 0.67,0.36至1.22;512名参与者;3项研究;中等质量证据)。我们发现中等质量证据表明,使用支架可使总住院时间缩短近四天(均值差(MD)-3.68,95%CI -6.52至-0.84;605名参与者;4项研究)。胃排空延迟、伤口感染和腹腔内脓肿的风险不确定(胃排空:RR 0.75,95%CI 0.24至2.35;中等质量证据)(伤口感染:RR 0.73,95%CI 0.40至1.32;中等质量证据)(脓肿:RR 1.38,0.49至3.85;低质量证据)。按支架类型进行的亚组分析提供了有限的证据,表明与内支架相比,外支架导致胰瘘风险更低。
外支架与内支架
由于证据质量低,与内支架相比,外支架对胰瘘、再次手术、胃排空延迟和腹腔内脓肿风险的影响不确定(胰瘘:RR 1.44,0.94至2.21;362名参与者;3项研究)(再次手术:RR 2.02,95%CI 0.38至10.79;319名参与者;3项研究)(胃排空:RR 1.65,0.66至4.09;362名参与者;3项研究)(脓肿:RR 1.91,95%CI 0.80至4.58;362名参与者;3项研究)。比较内支架和外支架的研究中,住院死亡率低于比较支架与无支架的研究。外支架组有1例死亡(RR 0.33,0.01至7.99;低质量证据)。使用内支架的参与者中无胰腺炎病例,而使用外支架的有3例(RR 0.15,0.01至2.73;低质量证据)。由于内支架平均减少1.7天住院时间的平均效应置信区间较宽(少9.18天至长5.84天;262名参与者;2项研究;低质量证据),内支架和外支架在总住院时间上的差异不确定。伤口感染分析无法排除任何一种方法的保护作用(RR 1.41,0.44至4.48;319名参与者;2项研究;中等质量证据)。
胰液置换与不置换
一项小型试验提供的证据不足,无法确定胰液置换的效果。
本系统评价发现关于支架效果的证据有限。我们未能找到令人信服的直接证据表明外支架优于内支架。我们发现RCT数量有限且样本量小。有必要进一步开展关于胰十二指肠切除术后使用支架的RCT。